82 FR 21819 - Nerve Agents and Certain Insecticides (Organophosphorus and/or Carbamate) Countermeasures
DEPARTMENT OF HEALTH AND HUMAN SERVICES Federal Register Volume 82, Issue 89 (May 10, 2017)
Federal Register Volume 82, Issue 89 (May 10, 2017)
| Page Range | 21819-21825 | |
| FR Document | 2017-09455 |
[Federal Register Volume 82, Number 89 (Wednesday, May 10, 2017)] [Notices] [Pages 21819-21825] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-09455] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Nerve Agents and Certain Insecticides (Organophosphorus and/or Carbamate) Countermeasures AGENCY: Department of Health and Human Services, Office of the Secretary. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Secretary is issuing a declaration pursuant to section 319F-3 of the Public Health Service Act to [[Page 21820]] provide liability protections consistent with that authority for medical countermeasures against nerve agents and organophosphorus insecticides that result in organophosphorus poisoning and carbamate insecticides that result in carbamate poisoning. DATES: The declaration is effective as of April 11, 2017. FOR FURTHER INFORMATION CONTACT: George W. Korch Jr., Ph.D., Acting Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, 200 Independence Avenue SW., Washington, DC 20201, Telephone (202) 205-2882 (this is not a toll-free number). SUPPLEMENTARY INFORMATION: Background The Public Readiness and Emergency Preparedness Act (PREP Act) authorizes the Secretary of the U.S. Department of Health and Human Services to issue a declaration to provide liability immunity to certain individuals and entities (Covered Persons) against any claim of loss caused by, arising out of, relating to, or resulting from the administration or use of medical countermeasures (Covered Countermeasures), except for claims that meet the PREP Act's definition of willful misconduct. Using this authority, the Secretary is issuing this declaration for medical countermeasures against nerve agents and organophosphorus insecticides that result in organophosphorus poisoning and carbamate insecticides that result in carbamate poisoning. The purpose of issuing this declaration is to strengthen preparedness against these threats that pose an ongoing credible risk of a future public health emergency and does not indicate a change in threat information. The declaration is published in full. We explain both the substantive and format changes in this supplementary section. The PREP Act was enacted on December 30, 2005 as Public Law 109- 148, Division C, Section 2. It amended the Public Health Service (``PHS'') Act, adding section 319F-3, which addresses liability immunity, and section 319F-4, which creates a compensation program. These sections are codified in the U.S. Code as 42 U.S.C. 247d-6d and 42 U.S.C. 247d-6e, respectively. The Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), Public Law 113-5, was enacted on March 13, 2013. Among other things, PAHPRA added sections 564A and 564B to the Federal Food, Drug & Cosmetic (FD&C) Act to provide new emergency authorities for dispensing approved products in emergencies and products held for emergency use. PAHPRA accordingly amended the definitions of Covered Countermeasures and qualified pandemic and epidemic products in section 319F-3 of the Public Health Service Act (the PREP Act provisions), so that products made available under these new FD&C Act authorities could be covered under PREP Act declarations. PAHPRA also extended the definition of qualified pandemic and epidemic products to include products or technologies intended to enhance the use or effect of a drug, biological product, or device used against the pandemic or epidemic or against adverse events from these products. Unless otherwise noted, all statutory citations below are to the U.S. Code. Section I, Determination of Public Health Emergency or Credible Risk of Future Public Health Emergency Before issuing a declaration under the PREP Act, the Secretary is required to determine that a disease or other health condition or threat to health constitutes a public health emergency or that there is a credible risk that the disease, condition, or threat may in the future constitute such an emergency.\1\ This determination is separate and apart from a declaration issued by the Secretary under section 319 of the PHS Act \2\ that a disease or disorder presents a public health emergency or that, a public health emergency, including significant outbreaks of infectious diseases or bioterrorist attacks, otherwise exists, or other declarations or determinations made under other authorities of the Secretary. The declaration states in section I the Secretary's determination that there is a credible risk that the release of nerve agents or organophosphorus insecticides and the resulting organophosphorus poisoning or the release of carbamate insecticides and the resulting carbamate poisoning may, in the future, constitute a public health emergency. --------------------------------------------------------------------------- \1\ 42 U.S.C. 247d-6d(b)(1). \2\ 42 U.S.C. 247d. --------------------------------------------------------------------------- Section II, Factors Considered In deciding whether and under what circumstances to issue a declaration with respect to a Covered Countermeasure, the Secretary must consider the desirability of encouraging the design, development, clinical testing or investigation, manufacture, labeling, distribution, formulation, packaging, marketing, promotion, sale, purchase, donation, dispensing, prescribing, administration, licensing, and use of the countermeasure.\3\ The declaration states these considerations in section II. --------------------------------------------------------------------------- \3\ 42 U.S.C. 247d-6d(b)(6). --------------------------------------------------------------------------- Section III, Recommended Activities The Secretary must recommend the activities for which the PREP Act's liability immunity is in effect. These activities may include, under conditions as the Secretary may specify, the manufacture, testing, development, distribution, administration, or use of one or more Covered Countermeasures (Recommended Activities).\4\ The declaration states the Recommended Activities in section III. --------------------------------------------------------------------------- \4\ 42 U.S.C. 247d-6d(b)(1). --------------------------------------------------------------------------- Section IV, Liability Immunity The Secretary must also state that liability protections available under the PREP Act are in effect with respect to the Recommended Activities.\5\ These liability protections provide that, ``[s]ubject to other provisions of [the PREP Act], a covered person shall be immune from suit and liability under Federal and State law with respect to all claims for loss caused by, arising out of, relating to, or resulting from the administration to or use by an individual of a covered countermeasure if a declaration . . . has been issued with respect to such countermeasure.'' \6\ The declaration includes the statement that liability immunity is in effect for Recommended Activities in section IV. --------------------------------------------------------------------------- \5\ 42 U.S.C. 247d-6d(b)(1). \6\ 42 U.S.C. 247d-6d(a)(1). --------------------------------------------------------------------------- Section V, Covered Persons The PREP Act's liability immunity applies to Covered Persons with respect to administration or use of a Covered Countermeasure. The term ``Covered Persons'' has a specific meaning, and is defined in the PREP Act to include manufacturers, distributors, program planners, and qualified persons, and their officials, agents, and employees, and the United States.\7\ The PREP Act further defines the terms ``manufacturer,'' ``distributor,'' ``program planner,'' and ``qualified person'' as described below.\8\ --------------------------------------------------------------------------- \7\ 42 U.S.C. 247d-6d(i)(2). \8\ 42 U.S.C. 247d-6d(i). --------------------------------------------------------------------------- A manufacturer includes a contractor or subcontractor of a manufacturer; a supplier or licenser of any product, intellectual property, service, research tool or component or other article used in the design, development, clinical testing, investigation or manufacturing of a Covered Countermeasure; and any or all of the parents, subsidiaries, [[Page 21821]] affiliates, successors, and assigns of a manufacturer; \9\ --------------------------------------------------------------------------- \9\ 42 U.S.C. 247d-6d(i)(4). --------------------------------------------------------------------------- A distributor means a person or entity engaged in the distribution of drugs, biologics, or devices, including but not limited to: Manufacturers; repackers; common carriers; contract carriers; air carriers; own-label distributors; private-label distributors; jobbers; brokers; warehouses and wholesale drug warehouses; independent wholesale drug traders; and, retail pharmacies; \10\ --------------------------------------------------------------------------- \10\ 42 U.S.C. 247d-6d(i)(3). --------------------------------------------------------------------------- A program planner means a state or local government, including a Native American Tribe; a person employed by the state or local government; or other person who supervises or administers a program with respect to the administration, dispensing, distribution, provision, or use of a Covered Countermeasure, including a person who establishes requirements, provides policy guidance, or supplies technical or scientific advice or assistance or provides a facility to administer or use a Covered Countermeasure in accordance with the Secretary's declaration.\11\ Under this definition, a private sector employer or community group or other person can be a program planner when it carries out the described activities. --------------------------------------------------------------------------- \11\ 42 U.S.C. 247d-6d(i)(6). --------------------------------------------------------------------------- A qualified person means a licensed health professional or other individual who is authorized to prescribe, administer, or dispense Covered Countermeasures under the law of the state in which the countermeasure was prescribed, administered, or dispensed; or, a person within a category of persons identified as qualified in the Secretary's declaration.\12\ Under this definition, the Secretary can describe in the declaration other qualified persons, such as volunteers, who are Covered Persons. Section V describes other qualified persons covered by this declaration. --------------------------------------------------------------------------- \12\ 42 U.S.C. 247d-6d(i)(8). --------------------------------------------------------------------------- The PREP Act also defines the word ``person'' as used in the Act: A person includes an individual, partnership, corporation, association, entity, or public or private corporation, including a federal, state, or local government agency or department.\13\ --------------------------------------------------------------------------- \13\ 42 U.S.C. 247d-6d(i)(5). --------------------------------------------------------------------------- The declaration lists Covered Persons in section V to include manufacturers, distributors, program planners, qualified persons, and their officials, agents, and employees, as those terms are defined in the PREP Act, and the United States. The declaration also lists in section V Additional Covered Persons to include: (a) Any person authorized in accordance with the public health and medical emergency response of the Authority Having Jurisdiction, . . . to prescribe, administer, deliver, distribute or dispense the Covered Countermeasures, and their officials, agents, employees, contractors and volunteers, following a declaration of an emergency; (b) any person authorized to prescribe, administer, or dispense the Covered Countermeasures or who is otherwise authorized to perform an activity under an Emergency Use Authorization in accordance with section 564 of the FD&C Act; and, (c) any person authorized to prescribe, administer, or dispense Covered Countermeasures in accordance with Section 564A of the FD&C Act. Section VI, Covered Countermeasures As noted above, section III describes the Secretary's Recommended Activities for which liability immunity is in effect. This section identifies the countermeasures for which the Secretary has recommended such activities. The PREP Act states that a Covered Countermeasure must be a ``qualified pandemic or epidemic product,'' or a ``security countermeasure,'' as described immediately below; or a drug, biological product or device authorized for emergency use in accordance with section 564, 564A, or 564B of the FD&C Act.\14\ --------------------------------------------------------------------------- \14\ 42 U.S.C. 247d-6d(i)(1). Sections 564, 564A, and 564B of the FD&C Act may be found at 21 U.S.C. 360bbb-3, 360bbb-3a, and 360bbb-3b. --------------------------------------------------------------------------- A qualified pandemic or epidemic product means a drug or device, as defined in the FD&C Act or a biological product, as defined in the PHS Act \15\ that is: (i) Manufactured, used, designed, developed, modified, licensed or procured to diagnose, mitigate, prevent, treat, or cure a pandemic or epidemic or limit the harm such a pandemic or epidemic might otherwise cause; (ii) manufactured, used, designed, developed, modified, licensed, or procured to diagnose, mitigate, prevent, treat, or cure a serious or life-threatening disease or condition caused by such a drug, biological product or device; (iii) or, a product or technology intended to enhance the use or effect of such a drug, biological product, or device.\16\ --------------------------------------------------------------------------- \15\ 21 U.S.C. 321(g)(1), (h); 42 U.S.C. 262(i). \16\ 42 U.S.C. 247d-6d(i)(1)(A), (i)(7). --------------------------------------------------------------------------- A security countermeasure is a drug or device, as defined in the FD&C Act or a biological product, as defined in the PHS Act \17\ that: (i)(a) The Secretary determines to be a priority to diagnose, mitigate, prevent or treat harm from any biological, chemical, radiological, or nuclear agent identified as a material threat by the Secretary of Homeland Security, or (b) to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device against such an agent; and (ii) is determined by the Secretary of Health and Human Services to be a necessary countermeasure to protect public health.\18\ --------------------------------------------------------------------------- \17\ 21 U.S.C. 321(g)(1), (h);42 U.S.C. 262(i). \18\ 42 U.S.C. 247d-6d(i)(1)(B),(c)(1)(B). --------------------------------------------------------------------------- To be a Covered Countermeasure, qualified pandemic or epidemic products and security countermeasures also must be approved or cleared under the FD&C Act; \19\ licensed under the PHS Act; \20\ authorized for emergency use under sections 564, 564A, or 564B of the FD&C Act.\21\ A qualified pandemic or epidemic product also may be a Covered Countermeasure when it is exempted under the FD&C Act for use as an investigational drug or device \22\ that is the object of research for possible use for diagnosis, mitigation, prevention, treatment, cure or limit harm of a pandemic or epidemic or serious or life-threatening condition caused by such a drug or device. A security countermeasure also may be a Covered Countermeasure if it may reasonably be determined to qualify for approval or licensing within ten years after the Department's determination that procurement of the countermeasure is appropriate. --------------------------------------------------------------------------- \19\ 21 U.S.C. 301 et seq. \20\ 42 U.S.C. 262. \21\ 21 U.S.C. 360bbb-3, 360bbb-3a, 360bbb-3b. \22\ 21 U.S.C. 355(i), 360j(g). --------------------------------------------------------------------------- The declaration describes the Covered Countermeasures in Section VI as: Any antidote; any other drug; all components and constituent materials of these antidotes and other drugs; all devices and their constituent components used in the administration of these antidotes and other drugs; any diagnostic; or any other device to identify, prevent, or treat organophosphorus or carbamate poisoning or adverse events from such countermeasures. The declaration also includes in section VI a statement referencing the statutory definitions of Covered Countermeasures to make clear that these statutory definitions limit the scope of Covered Countermeasures. Section VII, Limitations on Distribution The Secretary may specify that liability immunity is in effect only to Covered Countermeasures obtained [[Page 21822]] through a particular means of distribution.\23\ --------------------------------------------------------------------------- \23\ 42 U.S.C. 247d-6d(a)(5), (b)(2)(E). --------------------------------------------------------------------------- The declaration states in section VII that liability immunity is afforded to Covered Persons for Recommended Activities related to: (a) Present or future Federal contracts, cooperative agreements, grants, other transactions, interagency agreements, or memoranda of understanding or other Federal agreements or activities directly conducted by the Federal Government; or (b) Activities authorized in accordance with the public health and medical response of the Authority Having Jurisdiction to prescribe, administer, deliver, distribute, or dispense the Covered Countermeasures to respond to an event covered by a declared emergency, including authorized activities that occur as part of the response before the formal declaration of an emergency. The declaration also provides in section VII definitions for ``Authority Having Jurisdiction'' and ``Declaration of an Emergency:'' i. The Authority Having Jurisdiction means the public agency or its delegate that has legal responsibility and authority for responding to an incident, based on political or geographical (e.g., city, county, Tribal, State, or Federal boundary lines) or functional (e.g., law enforcement, public health) range or sphere of authority. ii. A declaration of emergency means any declaration by any authorized local, regional, State, or Federal official of an emergency specific to events that indicate an immediate need to administer and use the Covered Countermeasures, with the exception of a Federal declaration in support of an Emergency Use Authorization under section 564 of the FD&C Act unless such declaration specifies otherwise; Subsection (b) is intended to cover distribution, dispensing, administration, or use of the covered countermeasure under a formal government-authorized response to circumstances at any time those activities occur to respond to an event that gives rise to a declared emergency. Subsection (b) is not intended to be limited to cover those activities only after an emergency is formally declared and includes authorized activities that occur as part of the response before the formal declaration of an emergency. The Secretary recognizes that in emergency circumstances, distribution, dispensing, administration, or use of countermeasures may need to be expedient and may occur prior to a formal declaration of an emergency. This concern is particularly critical for the countermeasures covered by this declaration, where the Covered Countermeasures may need to be administered within minutes of exposure to a nerve agent to save lives. Thus, the Secretary is clarifying that coverage under subsection (b) is intended to cover any distribution, dispensing, administration, or use in accordance with the Authority Having Jurisdiction at any time that those activities address the emergency circumstances that gave rise to the declared emergency even if the activities occur prior to the declaration itself. For governmental program planners only, liability immunity is afforded only to the extent they obtain Covered Countermeasures through voluntary means, such as (1) donation; (2) commercial sale; (3) deployment of Covered Countermeasures from Federal stockpiles; or (4) deployment of donated, purchased, or otherwise voluntarily obtained Covered Countermeasures from State, local, or private stockpiles. This limitation on distribution is intended to deter program planners that are government entities from seizing privately held stockpiles of Covered Countermeasures. It does not apply to any other Covered Persons, including other program planners who are not government entities. Section VIII, Category of Disease, Health Condition, or Threat The Secretary must identify, for each Covered Countermeasure, the categories of diseases, health conditions, or threats to health for which the Secretary recommends the administration or use of the countermeasure.\24\ The declaration states in section VIII that the category of disease, health condition, or threat for which the Secretary recommends administration or use of the countermeasures is organophosphorus or carbamate poisoning. --------------------------------------------------------------------------- \24\ 42 U.S.C. 247d-6d(b)(2)(A). --------------------------------------------------------------------------- Section IX, Administration of Covered Countermeasures The PREP Act does not explicitly define the term ``administration'' but does assign the Secretary the responsibility to provide relevant conditions in the declaration. The declaration defines administration in section IX as: Administration of a Covered Countermeasure means physical provision of the countermeasures to recipients, or activities and decisions directly relating to public and private delivery, distribution and dispensing of the countermeasures to recipients; management and operation of countermeasure programs; or management and operation of locations for purpose of distributing and dispensing countermeasures. This definition of ``administration'' is intended to extend only to physical provision of a countermeasure to a recipient, such as vaccination or handing drugs to patients, and to activities related to management and operation of programs and locations for providing countermeasures to recipients, such as decisions and actions involving security and queuing, but only insofar as those activities directly relate to the countermeasure activities. Claims for which Covered Persons are provided immunity under the Act are losses caused by, arising out of, relating to, or resulting from the administration to or use by an individual of a Covered Countermeasure consistent with the terms of a declaration issued under the Act.\25\ Under the Secretary's definition, these liability claims are precluded if the claims allege an injury caused by physical provision of a countermeasure to a recipient, or if the claims are directly due to conditions of delivery, distribution, dispensing, or management and operation of countermeasure programs at distribution and dispensing sites. --------------------------------------------------------------------------- \25\ 42 U.S.C. 247d-6d(a). --------------------------------------------------------------------------- Thus, it is the Secretary's interpretation that, when a declaration is in effect, the Act precludes, for example, liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct. Likewise, the Act precludes a liability claim relating to the management and operation of a countermeasure distribution program or site, such as a slip-and-fall injury or vehicle collision by a recipient receiving a countermeasure at a retail store serving as an administration or dispensing location that alleges, for example, lax security or chaotic crowd control. However, a liability claim alleging an injury occurring at the site that was not directly related to the countermeasure activities is not covered, such as a slip and fall with no direct connection to the countermeasure's administration or use. In each case, whether immunity is applicable will depend on the particular facts and circumstances. [[Page 21823]] Section X, Population The Secretary must identify, for each Covered Countermeasure specified in a declaration, the population or populations of individuals for which liability immunity is in effect with respect to administration or use of the countermeasure.\26\ This section explains which individuals should use the countermeasure or to whom the countermeasure should be administered--in short, those who should be vaccinated or take a drug or other countermeasure. The declaration provides in section X that the population includes any individual who uses or who is administered a Covered Countermeasure in accordance with the declaration. --------------------------------------------------------------------------- \26\ 42 U.S.C. 247d-6d(b)(2)(C). --------------------------------------------------------------------------- In addition, the PREP Act specifies that liability immunity is afforded: (1) To manufacturers and distributors without regard to whether the countermeasure is used by or administered to this population; and (2) to program planners and qualified persons when the countermeasure is either used by or administered to this population or the program planner or qualified person reasonably could have believed the recipient was in this population.\27\ We included these statutory conditions in the declaration section X for clarity. --------------------------------------------------------------------------- \27\ 42 U.S.C. 247d-6d(a)(4). --------------------------------------------------------------------------- Section XI, Geographic Area The Secretary must identify, for each Covered Countermeasure specified in the declaration, the geographic area or areas for which liability immunity is in effect with respect to administration or use of the countermeasure, including, as appropriate, whether the declaration applies only to individuals physically present in the area or, in addition, applies to individuals who have a described connection to the area.\28\ The declaration states in section XI that there are no limitations on geographic area. --------------------------------------------------------------------------- \28\ 42 U.S.C. 247d-6d(b)(2)(D). --------------------------------------------------------------------------- In addition, the PREP Act specifies that liability immunity is afforded: (1) To manufacturers and distributors without regard to whether the countermeasure is used by or administered to individuals in the geographic areas; and (2) to program planners and qualified persons when the countermeasure is either used or administered in the geographic areas or the program planner or qualified person reasonably could have believed the countermeasure was used or administered in the areas.\29\ We included these statutory conditions in the declaration section XI for clarity. --------------------------------------------------------------------------- \29\ 42 U.S.C. 247d-6d(a)(4). --------------------------------------------------------------------------- Section XII, Effective Time Period The Secretary must identify, for each Covered Countermeasure, the period or periods during which liability immunity is in effect, designated by dates, milestones, or other description of events, including factors specified in the PREP Act.\30\ --------------------------------------------------------------------------- \30\ 42 U.S.C. 246d-6d(b)(2)(B), (b)(6). --------------------------------------------------------------------------- The declaration states in section XII when liability immunity takes effect for different means of distribution within that time period. Section XIII, Additional Time Period of Coverage The Secretary must specify a date after the ending date of the effective period of the declaration that is reasonable for manufacturers to arrange for disposition of the Covered Countermeasure, including return of the product to the manufacturer, and for other Covered Persons to take appropriate actions to limit administration or use of the Covered Countermeasure.\31\ In addition, the PREP Act specifies that for Covered Countermeasures that are subject to a declaration at the time they are obtained for the Strategic National Stockpile under 42 U.S.C. 247d-6b(a), the effective period of the declaration extends through the time the countermeasure is used or administered pursuant to a distribution or release from the Stockpile. Liability immunity under the provisions of the PREP Act and the conditions of the declaration continues during these additional time periods. Thus, liability immunity is afforded during the ``Effective Time Period,'' described under section XII of the declaration, plus the ``Additional Time Period of Coverage'' described under section XIII of the declaration. --------------------------------------------------------------------------- \31\ 42 U.S.C. 247d-6d(b)(3). --------------------------------------------------------------------------- The declaration states in section XIII that the additional time period is twelve (12) months and also states that extended coverage applies to any products obtained for the Strategic National Stockpile during the effective period of the declaration. We included the statutory provision for clarity. Section XIV, Countermeasures Injury Compensation Program Section 319F-4 of the PREP Act authorizes a Countermeasures Injury Compensation Program (CICP) to provide benefits to eligible individuals who sustain a serious physical injury or die as a direct result of the administration or use of a Covered Countermeasure.\32\ Compensation under the CICP for an injury directly caused by a Covered Countermeasure is based on the requirements set forth in this declaration, the administrative rules for the Program,\33\ and the statute.\34\ To show direct causation between a Covered Countermeasure and a serious physical injury, the statute requires ``compelling, reliable, valid, medical and scientific evidence.'' \35\ The administrative rules for the Program further explain the necessary requirements for eligibility under the CICP. Please note that, by statute, requirements for compensation under the CICP may not always align with the requirements for liability immunity provided under the PREP Act. The declaration explains in section XIV, ``Countermeasures Injury Compensation Program'' the types of injury and standard of evidence needed to be considered for compensation under the CICP. Further, the administrative rules for the CICP specify if countermeasures are administered or used outside the United States, only otherwise eligible individuals at American embassies, military installations abroad (such as military bases, ships, and camps) or at North Atlantic Treaty Organization (NATO) installations (subject to the NATO Status of Forces Agreement) where American servicemen and servicewomen are stationed may be considered for CICP benefits. Other individuals outside the United States may not be eligible for CICP benefits. --------------------------------------------------------------------------- \32\ 42 U.S.C. 247d-6e. \33\ 42 CFR part 110. \34\ 42 U.S.C. 247d-6e. \35\ 42 U.S.C. 247d-6e(b)(4). --------------------------------------------------------------------------- Section XV, Amendments The Secretary may amend any portion of a declaration through publication in the Federal Register.\36\ The declaration states in section XV that any amendments to this declaration will be published in the Federal Register. --------------------------------------------------------------------------- \36\ 42 U.S.C. 247d-6d(b)(4). --------------------------------------------------------------------------- Declaration Declaration for Public Readiness and Emergency Preparedness Act Coverage for Nerve Agents and Certain Insecticides (Organophosphorus and/or Carbamate) Countermeasures I. Determination of Public Health Emergency or Credible Risk of Future Public Health Emergency 42 U.S.C. 247d-6d(b)(1) I have determined that there is a credible risk that the release of nerve agents or organophosphorus insecticides and the resulting organophosphorus [[Page 21824]] poisoning or release of carbamate insecticides and the resulting carbamate poisoning may, in the future, constitute a public health emergency. II. Factors Considered 42 U.S.C. 247d-6d(b)(6) I have considered the desirability of encouraging the design, development, clinical testing or investigation, manufacture, labeling, distribution, formulation, packaging, marketing, promotion, sale, purchase, donation, dispensing, prescribing, administration, licensing, and use of the Covered Countermeasures. III. Recommended Activities 42 U.S.C. 247d-6d(b)(1) I recommend, under the conditions stated in this declaration, the manufacture, testing, development, distribution, administration, or use of the Covered Countermeasures. IV. Liability Immunity 42 U.S.C. 247d-6d(a), 247d-6d(b)(1) Liability immunity as prescribed in the PREP Act and conditions stated in this declaration is in effect for the Recommended Activities described in section III. V. Covered Persons 42 U.S.C. 247d-6d(i)(2), (3), (4), (6), (8)(A) and (B) Covered Persons who are afforded liability immunity under this declaration are ``manufacturers,'' ``distributors,'' ``program planners,'' ``qualified persons,'' and their officials, agents, and employees, as those terms are defined in the PREP Act, and the United States. In addition, I have determined that the following additional persons are qualified persons: (a) Any person authorized in accordance with the public health and medical emergency response of the Authority Having Jurisdiction, as described in section VII below, to prescribe, administer, deliver, distribute or dispense the Covered Countermeasures, and their officials, agents, employees, contractors and volunteers, following a declaration of an emergency; (b) Any person authorized to prescribe, administer, or dispense the Covered Countermeasures or who is otherwise authorized to perform an activity under an Emergency Use Authorization in accordance with section 564 of the FD&C Act; (c) Any person authorized to prescribe, administer, or dispense Covered Countermeasures in accordance with Section 564A of the FD&C Act. VI. Covered Countermeasures 42 U.S.C. 247d-6b(c)(1)(B), 42 U.S.C. 247d-6d(i)(1) and (7) Covered Countermeasures are: Any antidote; any other drug; all components and constituent materials of these antidotes and other drugs; all devices and their constituent components used in the administration of these antidotes and other drugs; any diagnostic; or any other device to identify, prevent, or treat organophosphorus or carbamate poisoning or adverse events from such countermeasures. Covered Countermeasures must be ``qualified pandemic or epidemic products,'' or ``security countermeasures,'' or drugs, biological products, or devices authorized for investigational or emergency use, as those terms are defined in the PREP Act, the FD&C Act, and the Public Health Service Act. VII. Limitations on Distribution 42 U.S.C. 247d-6d(a)(5) and (b)(2)(E) I have determined that liability immunity is afforded to Covered Persons only for Recommended Activities involving Covered Countermeasures that are related to: (a) Present or future Federal contracts, cooperative agreements, grants, other transactions, interagency agreements, memoranda of understanding, or other Federal agreements, or activities directly conducted by the Federal Government; or (b) Activities authorized in accordance with the public health and medical response of the Authority Having Jurisdiction to prescribe, administer, deliver, distribute or dispense the Covered Countermeasures to respond to an event covered by a declared emergency, including authorized activities that occur as part of the response before the formal declaration of an emergency. i. The Authority Having Jurisdiction means the public agency or its delegate that has legal responsibility and authority for responding to an incident, based on political or geographical (e.g., city, county, Tribal, State, or Federal boundary lines) or functional (e.g., law enforcement, public health) range or sphere of authority. ii. A declaration of emergency means any declaration by any authorized local, regional, State, or Federal official of an emergency specific to events that indicate an immediate need to administer and use the Covered Countermeasures, with the exception of a Federal declaration in support of an Emergency Use Authorization under section 564 of the FD&C Act unless such declaration specifies otherwise; I have also determined that for governmental program planners only, liability immunity is afforded only to the extent such program planners obtain Covered Countermeasures through voluntary means, such as (1) donation; (2) commercial sale; (3) deployment of Covered Countermeasures from Federal stockpiles; or (4) deployment of donated, purchased, or otherwise voluntarily obtained Covered Countermeasures from State, local, or private stockpiles. VIII. Category of Disease, Health Condition, or Threat 42 U.S.C. 247d-6d(b)(2)(A) The category of disease, health condition, or threat for which I recommend the administration or use of the Covered Countermeasures is organophosphorus or carbamate poisoning. IX. Administration of Covered Countermeasures 42 U.S.C. 247d-6d(a)(2)(B) Administration of the Covered Countermeasure means physical provision of the countermeasures to recipients, or activities and decisions directly relating to public and private delivery, distribution and dispensing of the countermeasures to recipients, management and operation of countermeasure programs, or management and operation of locations for purpose of distributing and dispensing countermeasures. X. Population 42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(C) The populations of individuals include any individual who uses or is administered the Covered Countermeasures in accordance with this declaration. Liability immunity is afforded to manufacturers and distributors without regard to whether the countermeasure is used by or administered to this population; liability immunity is afforded to program planners and qualified persons when the countermeasure is used by or administered to this population or the program planner or qualified person reasonably could have believed the recipient was in this population. [[Page 21825]] XI. Geographic Area 42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(D) Liability immunity is afforded for the administration or use of a Covered Countermeasure without geographic limitation. Liability immunity is afforded to manufacturers and distributors without regard to whether the countermeasure is used by or administered in these geographic areas; liability immunity is afforded to program planners and qualified persons when the countermeasure is used by or administered in these geographic areas, or the program planner or qualified person reasonably could have believed the recipient was in these geographic areas. XII. Effective Time Period 42 U.S.C. 247d-6d(b)(2)(B) Liability immunity for Covered Countermeasures obtained through means of distribution other than in accordance with the public health and medical response of the Authority Having Jurisdiction extends through December 31, 2022. Liability immunity for Covered Countermeasures administered and used in accordance with the public health and medical response of the Authority Having Jurisdiction begins on the date the response to an event covered by an emergency declaration begins, including authorized activities that occur as part of the response before the formal declaration of an emergency, and lasts through (1) the final day the emergency declaration is in effect or (2) December 31, 2022, whichever occurs first. XIII. Additional Time Period of Coverage 42 U.S.C. 247d-6d(b)(3)(A), (B) and (C) I have determined that an additional twelve (12) months of liability protection is reasonable to allow for the manufacturer(s) to arrange for disposition of the Covered Countermeasure, including return of the Covered Countermeasures to the manufacturer, and for Covered Persons to take such other actions as are appropriate to limit the administration or use of the Covered Countermeasures. Covered Countermeasures obtained for the Strategic National Stockpile (``SNS'') during the effective period of this declaration for Covered Countermeasures obtained through means of distribution other than in accordance with the public health and medical response of the Authority Having Jurisdiction are covered through the date of administration or use pursuant to a distribution or release from the SNS. XIV. Countermeasures Injury Compensation Program 42 U.S.C. 247d-6e The PREP Act authorizes a Countermeasures Injury Compensation Program (``CICP'') to provide benefits to certain individuals or estates of individuals who sustain a serious physical covered injury as the direct result of the administration or use of a Covered Countermeasure and/or benefits to certain survivors of individuals who die as a direct result of the administration or use of the Covered Countermeasure. The causal connection between the countermeasure and the serious physical injury must be supported by compelling, reliable, valid, medical and scientific evidence in order for the individual to be considered for compensation. The CICP is administered by the Health Resources and Services Administration (``HRSA''), within the Department of Health and Human Services. Information about the CICP is available at the toll free number 1-855-266-2427 or http://www.hrsa.gov/cicp/. XV. Amendments 42 U.S.C. 247d-6d(b)(4) Any amendments to this declaration will be published in the Federal Register. Authority: 42 U.S.C. 247d-6d. Dated: May 4, 2017. Thomas E. Price, Secretary. [FR Doc. 2017-09455 Filed 5-9-17; 8:45 am] BILLING CODE 4150-03-P
![Federal Register / Vol. 82, No. 89 / Wednesday, May 10, 2017 / Notices 21819
name and contact information to be I. Background II. Potential Modifications to the FDA
made publicly available, you can Blueprint
provide this information on the cover On July 12, 2012, FDA approved an
ER/LA Opioid Analgesics REMS, FDA is considering modifications to
sheet and not in the body of your the existing Blueprint in light of
comments and you must identify this including an FDA-created ‘‘Blueprint for
recommendations from the May 2016
information as ‘‘confidential.’’ Any Prescriber Education for Extended-
Advisory Committee meeting. The draft
information marked as ‘‘confidential’’ Release and Long-Acting (ER/LA)
revisions to the Blueprint being made
will not be disclosed except in Opioid Analgesics.’’ The goal of the available pursuant to this notice would
accordance with 21 CFR 10.20 and other REMS is to reduce serious adverse broaden the Blueprint to include
applicable disclosure law. For more outcomes resulting from inappropriate information on pain management,
information about FDA’s posting of prescribing, misuse, and abuse of ER/LA including the principles of acute and
comments to public dockets, see 80 FR opioid analgesics while maintaining chronic pain management; non-
56469, September 18, 2015, or access patient access to pain medications. pharmacologic treatments for pain; and
the information at: https://www.gpo.gov/ The ER/LA Opioid Analgesics REMS pharmacologic treatments for pain (both
fdsys/pkg/FR-2015-09-18/pdf/2015- requires that training in the form of non-opioid analgesic and opioid
23389.pdf. accredited continuing education be analgesic). FDA intends to consider
Docket: For access to the docket to made available to health care providers public input as it considers
read background documents or the who prescribe ER/LA opioid analgesics. modifications to the ER/LA Opioid
electronic and written/paper comments The accredited continuing education Analgesics REMS.
received, go to https:// must include all elements of the FDA III. May 2017 Public Workshop
www.regulations.gov and insert the Blueprint, which includes a basic
On April 18, 2017, FDA published a
docket number, found in brackets in the outline and the core messages related to
notice announcing a public workshop
heading of this document, into the ER/LA opioid analgesics. FDA
scheduled for May 9–10, 2017, to seek
‘‘Search’’ box and follow the prompts developed the Blueprint following
input on issues and challenges
and/or go to the Division of Dockets extensive input from stakeholders and associated with Federal efforts to
Management, 5630 Fishers Lane, Rm. sought input on a draft version on support training on pain management
1061, Rockville, MD 20852. November 7, 2011 (76 FR 68766), before and the safe prescribing, dispensing,
Submit written requests for single approving it in 2012 as part of the ER/ and patient use of opioids (safe use of
copies of the draft revised Blueprint to LA Opioid Analgesics REMS. opioids) for health care providers.
the Division of Drug Information, Center On May 3–4, 2016, FDA convened a Through the public workshop, FDA
for Drug Evaluation and Research, Food joint meeting of the Drug Safety and hopes to obtain additional insight from
and Drug Administration, 10001 New Risk Management Advisory Committee a variety of stakeholders on how best to
Hampshire Ave., Hillandale Building, and the Anesthetic and Analgesic Drug ensure that health care providers receive
4th Floor, Silver Spring, MD 20993– Products Advisory Committee to discuss training in pain management and the
0002. Send one self-addressed adhesive whether this REMS assures safe use of safe use of opioids. The draft revisions
label to assist that office in processing these products; whether or not it is to the Blueprint being made available at
your requests. See the SUPPLEMENTARY unduly burdensome to patient access to https://www.fda.gov/Drugs/NewsEvents/
INFORMATION section for electronic the drugs; and whether it (to the extent ucm553931.htm are intended to provide
access to the draft revised Blueprint. practicable) minimizes the burden to the important context for the public
health care delivery system (March 14, workshop’s discussion. However, the
FOR FURTHER INFORMATION CONTACT: Blueprint itself will not be a discussion
2016, 81 FR 13372). FDA also sought
Janelle Derbis, Center for Drug input on possible modifications to the topic at the workshop. FDA intends to
Evaluation and Research (HFD–1), Food ER/LA Opioid Analgesic REMS, consider any comments submitted to
and Drug Administration 20 North including expansion of the scope and this docket as it considers possible
Michigan Ave., Suite 510, Chicago, IL content of prescriber training and modifications to the ER/LA Opioid
60602, 312–596–6516. expansion of the REMS program to Analgesics REMS.
SUPPLEMENTARY INFORMATION: FDA is include immediate release (IR) opioid Dated: May 4, 2017.
announcing the availability of draft analgesics. Advisory Committee Anna K. Abram,
revisions to the ‘‘FDA Blueprint for members were in favor of modifying the Deputy Commissioner for Policy, Planning,
Prescriber Education for Extended- REMS program to include the IR opioid Legislation, and Analysis.
Release and Long-Acting Opioid analgesics as well as broadening the [FR Doc. 2017–09442 Filed 5–9–17; 8:45 am]
Analgesics’’ (draft revisions to the training program to include pain BILLING CODE 4164–01–P
Blueprint). In addition to seeking management. The majority of the
comment on the draft revisions to the members were in favor of a requirement
Blueprint, FDA expects the draft for all prescribers to complete training. DEPARTMENT OF HEALTH AND
revisions to create important context for Many of the members recommended HUMAN SERVICES
discussions at a public workshop on that the required training program be
issues and challenges associated with implemented through mechanisms Nerve Agents and Certain Insecticides
Federal efforts to support training on outside the FDA REMS authority. The (Organophosphorus and/or
pain management and the safe majority of members also stated that Carbamate) Countermeasures
jstallworth on DSK7TPTVN1PROD with NOTICES
prescribing, dispensing, and patient use other health care providers involved in AGENCY: Department of Health and
of opioids (safe use of opioids) for the management of pain should be Human Services, Office of the Secretary.
health care providers. That workshop, included as a target audience for ACTION: Notice.
which is scheduled for May 9–10, 2017, education, though they did not specify
was previously announced in the that the training should be mandatory SUMMARY: The Secretary is issuing a
Federal Register on April 18, 2017 (82 for non-prescribing health care declaration pursuant to section 319F–3
FR 18300). providers. of the Public Health Service Act to
VerDate Sep<11>2014 15:21 May 09, 2017 Jkt 241001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\10MYN1.SGM 10MYN1](https://thefederalregister.org/doc/82_FR_21908/page/1.svg)
![21820 Federal Register / Vol. 82, No. 89 / Wednesday, May 10, 2017 / Notices
provide liability protections consistent new emergency authorities for administration, licensing, and use of the
with that authority for medical dispensing approved products in countermeasure.3 The declaration states
countermeasures against nerve agents emergencies and products held for these considerations in section II.
and organophosphorus insecticides that emergency use. PAHPRA accordingly
Section III, Recommended Activities
result in organophosphorus poisoning amended the definitions of Covered
and carbamate insecticides that result in Countermeasures and qualified The Secretary must recommend the
carbamate poisoning. pandemic and epidemic products in activities for which the PREP Act’s
DATES: The declaration is effective as of section 319F–3 of the Public Health liability immunity is in effect. These
April 11, 2017. Service Act (the PREP Act provisions), activities may include, under conditions
FOR FURTHER INFORMATION CONTACT: so that products made available under as the Secretary may specify, the
George W. Korch Jr., Ph.D., Acting these new FD&C Act authorities could manufacture, testing, development,
Assistant Secretary for Preparedness be covered under PREP Act distribution, administration, or use of
and Response, Office of the Secretary, declarations. PAHPRA also extended one or more Covered Countermeasures
Department of Health and Human the definition of qualified pandemic and (Recommended Activities).4 The
Services, 200 Independence Avenue epidemic products to include products declaration states the Recommended
SW., Washington, DC 20201, Telephone or technologies intended to enhance the Activities in section III.
(202) 205–2882 (this is not a toll-free use or effect of a drug, biological
product, or device used against the Section IV, Liability Immunity
number).
pandemic or epidemic or against The Secretary must also state that
SUPPLEMENTARY INFORMATION: adverse events from these products. liability protections available under the
Background Unless otherwise noted, all statutory
PREP Act are in effect with respect to
citations below are to the U.S. Code.
The Public Readiness and Emergency the Recommended Activities.5 These
Preparedness Act (PREP Act) authorizes Section I, Determination of Public liability protections provide that,
the Secretary of the U.S. Department of Health Emergency or Credible Risk of ‘‘[s]ubject to other provisions of [the
Health and Human Services to issue a Future Public Health Emergency PREP Act], a covered person shall be
declaration to provide liability Before issuing a declaration under the immune from suit and liability under
immunity to certain individuals and PREP Act, the Secretary is required to Federal and State law with respect to all
entities (Covered Persons) against any determine that a disease or other health claims for loss caused by, arising out of,
claim of loss caused by, arising out of, condition or threat to health constitutes relating to, or resulting from the
relating to, or resulting from the a public health emergency or that there administration to or use by an
administration or use of medical is a credible risk that the disease, individual of a covered countermeasure
countermeasures (Covered condition, or threat may in the future if a declaration . . . has been issued
Countermeasures), except for claims constitute such an emergency.1 This with respect to such countermeasure.’’ 6
that meet the PREP Act’s definition of determination is separate and apart from The declaration includes the statement
willful misconduct. Using this a declaration issued by the Secretary that liability immunity is in effect for
authority, the Secretary is issuing this under section 319 of the PHS Act 2 that Recommended Activities in section IV.
declaration for medical a disease or disorder presents a public Section V, Covered Persons
countermeasures against nerve agents health emergency or that, a public
and organophosphorus insecticides that health emergency, including significant The PREP Act’s liability immunity
result in organophosphorus poisoning outbreaks of infectious diseases or applies to Covered Persons with respect
and carbamate insecticides that result in bioterrorist attacks, otherwise exists, or to administration or use of a Covered
carbamate poisoning. The purpose of other declarations or determinations Countermeasure. The term ‘‘Covered
issuing this declaration is to strengthen made under other authorities of the Persons’’ has a specific meaning, and is
preparedness against these threats that Secretary. The declaration states in defined in the PREP Act to include
pose an ongoing credible risk of a future section I the Secretary’s determination manufacturers, distributors, program
public health emergency and does not that there is a credible risk that the planners, and qualified persons, and
indicate a change in threat information. release of nerve agents or their officials, agents, and employees,
The declaration is published in full. organophosphorus insecticides and the and the United States.7 The PREP Act
We explain both the substantive and resulting organophosphorus poisoning further defines the terms
format changes in this supplementary or the release of carbamate insecticides ‘‘manufacturer,’’ ‘‘distributor,’’
section. and the resulting carbamate poisoning ‘‘program planner,’’ and ‘‘qualified
The PREP Act was enacted on may, in the future, constitute a public person’’ as described below.8
December 30, 2005 as Public Law 109– health emergency. A manufacturer includes a contractor
148, Division C, Section 2. It amended or subcontractor of a manufacturer; a
the Public Health Service (‘‘PHS’’) Act, Section II, Factors Considered
supplier or licenser of any product,
adding section 319F–3, which addresses In deciding whether and under what intellectual property, service, research
liability immunity, and section 319F–4, circumstances to issue a declaration tool or component or other article used
which creates a compensation program. with respect to a Covered in the design, development, clinical
These sections are codified in the U.S. Countermeasure, the Secretary must testing, investigation or manufacturing
Code as 42 U.S.C. 247d–6d and 42 consider the desirability of encouraging of a Covered Countermeasure; and any
U.S.C. 247d–6e, respectively. The
jstallworth on DSK7TPTVN1PROD with NOTICES
the design, development, clinical testing or all of the parents, subsidiaries,
Pandemic and All-Hazards or investigation, manufacture, labeling,
Preparedness Reauthorization Act distribution, formulation, packaging, 3 42 U.S.C. 247d–6d(b)(6).
(PAHPRA), Public Law 113–5, was marketing, promotion, sale, purchase, 4 42 U.S.C. 247d–6d(b)(1).
enacted on March 13, 2013. Among donation, dispensing, prescribing, 5 42 U.S.C. 247d–6d(b)(1).
other things, PAHPRA added sections 6 42 U.S.C. 247d–6d(a)(1).
564A and 564B to the Federal Food, 1 42 U.S.C. 247d–6d(b)(1). 7 42 U.S.C. 247d–6d(i)(2).
Drug & Cosmetic (FD&C) Act to provide 2 42 U.S.C. 247d. 8 42 U.S.C. 247d–6d(i).
VerDate Sep<11>2014 15:21 May 09, 2017 Jkt 241001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\10MYN1.SGM 10MYN1](https://thefederalregister.org/doc/82_FR_21908/page/2.svg)
![Federal Register / Vol. 82, No. 89 / Wednesday, May 10, 2017 / Notices 21825
XI. Geographic Area Having Jurisdiction are covered through property such as patentable material,
the date of administration or use and personal information concerning
42 U.S.C. 247d–6d(a)(4), 247d–
pursuant to a distribution or release individuals associated with the grant
6d(b)(2)(D)
from the SNS. applications, the disclosure of which
Liability immunity is afforded for the would constitute a clearly unwarranted
administration or use of a Covered XIV. Countermeasures Injury
Compensation Program invasion of personal privacy.
Countermeasure without geographic
Name of Committee: National Institute of
limitation. 42 U.S.C. 247d–6e Child Health and Human Development
Liability immunity is afforded to Special Emphasis Panel; Learning Disabilities
The PREP Act authorizes a
manufacturers and distributors without Research Centers.
Countermeasures Injury Compensation
regard to whether the countermeasure is Date: June 22–23, 2017.
Program (‘‘CICP’’) to provide benefits to
used by or administered in these Time: 7:00 a.m. to 6:00 p.m.
certain individuals or estates of
geographic areas; liability immunity is Agenda: To review and evaluate grant
individuals who sustain a serious applications.
afforded to program planners and
physical covered injury as the direct Place: Beacon Hotel and Corporate
qualified persons when the
result of the administration or use of a Quarters, 1615 Rhode Island Avenue NW.,
countermeasure is used by or
Covered Countermeasure and/or Washington, DC 20036
administered in these geographic areas,
benefits to certain survivors of Contact Person: Marita R. Hopmann, Ph.D.,
or the program planner or qualified Scientific Review Officer, Division of
individuals who die as a direct result of
person reasonably could have believed Scientific Review, Eunice Kennedy Shriver
the administration or use of the Covered
the recipient was in these geographic National Institute of Child Health & Human
Countermeasure. The causal connection
areas. Development, 6710B Rockledge Drive,
between the countermeasure and the
Bethesda, MD 20892, Phone: 301–435–6911,
XII. Effective Time Period serious physical injury must be Email: HopmannM@mail.nih.gov.
supported by compelling, reliable, valid,
42 U.S.C. 247d–6d(b)(2)(B) Name of Committee: National Institute of
medical and scientific evidence in order Child Health and Human Development Initial
Liability immunity for Covered for the individual to be considered for Review Group; Developmental Biology
Countermeasures obtained through compensation. The CICP is Subcommittee.
means of distribution other than in administered by the Health Resources Date: July 24, 2017.
accordance with the public health and and Services Administration (‘‘HRSA’’), Time: 8:00 a.m. to 5:30 p.m.
medical response of the Authority within the Department of Health and Agenda: To review and evaluate grant
Having Jurisdiction extends through Human Services. Information about the applications.
December 31, 2022. CICP is available at the toll free number Place: Embassy Suites, Chevy Chase, MD.
Liability immunity for Covered Contact Person: Cathy J. Wedeen, Ph.D.,
1–855–266–2427 or http://
Countermeasures administered and Scientific Review Officer, Division of
www.hrsa.gov/cicp/. Scientific Review, Eunice Kennedy Shriver
used in accordance with the public
XV. Amendments National Institute of Child Health and
health and medical response of the Human Development, 6710B Rockledge
Authority Having Jurisdiction begins on 42 U.S.C. 247d–6d(b)(4) Drive, Bethesda, MD 20892, 301–435–6878,
the date the response to an event wedeenc@mail.nih.gov.
Any amendments to this declaration
covered by an emergency declaration (Catalogue of Federal Domestic Assistance
will be published in the Federal
begins, including authorized activities Program Nos. 93.864, Population Research;
Register.
that occur as part of the response before 93.865, Research for Mothers and Children;
the formal declaration of an emergency, Authority: 42 U.S.C. 247d–6d. 93.929, Center for Medical Rehabilitation
and lasts through (1) the final day the Dated: May 4, 2017. Research; 93.209, Contraception and
emergency declaration is in effect or (2) Thomas E. Price, Infertility Loan Repayment Program, National
December 31, 2022, whichever occurs Institutes of Health, HHS)
Secretary.
first. [FR Doc. 2017–09455 Filed 5–9–17; 8:45 am] Dated: May 4, 2017.
XIII. Additional Time Period of BILLING CODE 4150–03–P Michelle Trout,
Coverage Program Analyst, Office of Federal Advisory
Committee Policy.
42 U.S.C. 247d–6d(b)(3)(A), (B) and (C) DEPARTMENT OF HEALTH AND [FR Doc. 2017–09413 Filed 5–9–17; 8:45 am]
I have determined that an additional HUMAN SERVICES BILLING CODE 4140–01–P
twelve (12) months of liability
protection is reasonable to allow for the National Institutes of Health
manufacturer(s) to arrange for DEPARTMENT OF HEALTH AND
Eunice Kennedy Shriver National HUMAN SERVICES
disposition of the Covered
Institute of Child Health & Human
Countermeasure, including return of the
Development; Notice of Closed National Institutes of Health
Covered Countermeasures to the
Meetings
manufacturer, and for Covered Persons
Center for Scientific Review; Notice of
to take such other actions as are Pursuant to section 10(d) of the Closed Meetings
appropriate to limit the administration Federal Advisory Committee Act, as
or use of the Covered Countermeasures. amended (5 U.S.C. App.), notice is Pursuant to section 10(d) of the
Covered Countermeasures obtained
jstallworth on DSK7TPTVN1PROD with NOTICES
hereby given of the following meetings. Federal Advisory Committee Act, as
for the Strategic National Stockpile The meetings will be closed to the amended (5 U.S.C. App.), notice is
(‘‘SNS’’) during the effective period of public in accordance with the hereby given of the following meetings.
this declaration for Covered provisions set forth in sections The meetings will be closed to the
Countermeasures obtained through 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., public in accordance with the
means of distribution other than in as amended. The grant applications and provisions set forth in sections
accordance with the public health and the discussions could disclose 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
medical response of the Authority confidential trade secrets or commercial as amended. The grant applications and
VerDate Sep<11>2014 15:21 May 09, 2017 Jkt 241001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\10MYN1.SGM 10MYN1](https://thefederalregister.org/doc/82_FR_21908/page/7.svg)
Document Created: 2017-05-10 00:00:51
Document Modified: 2017-05-10 00:00:51
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | The declaration is effective as of April 11, 2017. | |
| Contact | George W. Korch Jr., Ph.D., Acting Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, 200 Independence Avenue SW., Washington, DC 20201, Telephone (202) 205-2882 (this is not a toll-free number). | |
| FR Citation | 82 FR 21819 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR